Life Sciences Tools and Services

West Pharmaceutical

CSL Services Operations Steadily Recover After Cyber Attack, Shares Rise Over 1%

W. R. Grace Executives Sell Company Stocks

West Pharmaceutical released FY2026 Q1 earnings on April 23 Pre-Market EST, actual revenue USD 844.9 M (forecast USD 779.37 M), actual EPS USD 1.92 (forecast USD 1.6675)

West Pharmaceutical Services Reports Q1 Net Sales Up 21% and Raises Full-Year Revenue Guidance

West Pharmaceutical to Release FY2026 Q1 Earnings on April 23 Pre-Market EST, Forecast Revenue USD 779.37 M, EPS USD 1.6675

West Pharmaceutical Services Releases 2025 Annual Report

West Pharmaceutical released FY2025 earnings on February 12 Pre-Market (EST), actual revenue USD 3.074 B (forecast USD 3.064 B), actual EPS USD 6.79 (forecast USD 6.8815)

West Pharmaceutical released FY2025 Q4 earnings on February 12 Pre-Market EST, actual revenue and EPS data unavailable

West Pharmaceutical to release FY2025 Q4 earnings on February 12 Pre-Market EST, forecast revenue USD 795.7 M, EPS USD 1.834

West Pharmaceutical Services to Release Earnings Report

West Pharmaceutical released FY2025 9 Months Earnings on October 23 Pre-Market (EST), actual revenue USD 2.269 B, actual EPS USD 4.97

West Pharmaceutical released FY2025 Q3 earnings on October 23 Pre-Market (EST), actual revenue USD 804.6 M (forecast USD 789.89 M), actual EPS USD 1.92 (forecast USD 1.7385)

West Pharmaceutical to Release FY2025 Q3 Earnings on October 23 Pre-Market (EST), Forecast Revenue USD 788.38 M, EPS USD 1.6307

West Pharmaceutical released FY2025 Q2 earnings on July 24 Pre-Market EST, actual revenue USD 766.5 M (forecast USD 730.07 M), actual EPS USD 1.82 (forecast USD 1.5466)

West Pharmaceutical released FY2025 Semi-Annual earnings on July 24 Pre-Market EST, actual revenue USD 1.465 B, actual EPS USD 3.05

West Pharmaceutical to release FY2025 Q2 earnings on July 24 Pre-Market EST, forecast revenue USD 725.28 M, EPS USD 1.4699

West Pharmaceutical Services Transitions from Pandemic Growth Phase to Strong Free Cash Flow Era

West Pharmaceutical Services Displays Stable but EBIT Dwindling Financial Condition

Texas Teachers Retirement System Significantly Increases C&J Energy Stake

West Pharmaceutical Services Accused of Misleading Investors

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ELIL

LLYX

Donald Trump disclosed stock purchases of up to $680,000 in Eli Lilly as Medicare initiatives advanced GLP-1 drug coverage. The investments coincided with policies benefiting the drugmaker's obesity treatments. Trump's purchases also included shares in West Pharmaceutical Services, valued between $250,000 and $500,000. A spokesperson stated that his investments are managed independently by third-party institutions. Eli Lilly shares rose 2.73% to $1015.09, gaining 9.4% over the past month.

benzinga_article

Eli Lilly

Direxion Daily LLY Bull 2X Shares

iShares US Pharma

Defiance Daily Target 2X Long LLY ETF

Health Care Select Sector SPDR

VG Health

Thomson Reuters

S&P 500

Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report

LABU

SBIO

Radnor Capital Management LLC increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 130.6% in Q4, now holding 6,000 shares valued at $1.65 million. Other institutional investors also raised their positions. West Pharmaceutical's stock opened at $304.31, with a market cap of $21.50 billion and a P/E ratio of 40.68. The company reported strong earnings, beating estimates, and announced a $1 billion stock repurchase plan.

Market Beat

iShares US Medical Devices

SPDR S&P Health Equip

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Arcadian Asset

Radnor Capital Management LLC Has $1.65 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST

Zacks Research upgraded West Pharmaceutical Services (NYSE:WST) from a 'hold' to a 'strong-buy' rating. Other analysts, including Evercore and UBS, reaffirmed positive ratings with price targets ranging from $310 to $340. The company reported strong quarterly earnings, beating estimates with $2.13 EPS and $844.90 million in revenue. West Pharmaceutical also initiated a $1 billion share repurchase plan, indicating confidence in its stock value.

Evercore

UBS Group AG

Deutsche Bank AG

Citigroup

Barclays

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

West Pharmaceutical Services (NYSE:WST) Upgraded to "Strong-Buy" at Zacks Research

West Pharmaceutical Services Inc. (WST) shares fell 3.10% to $302.40 on Wednesday, marking the third consecutive day of losses. The stock is currently 8.61% below its 52-week high of $330.88 reached on May 11. In comparison, competitors Abbott Laboratories (ABT), Becton Dickinson & Co. (BDX), and Baxter International Inc. (BAX) also experienced declines of 0.62%, 2.26%, and 3.24%, respectively. The S&P 500 Index rose 0.58% while the Dow Jones Industrial Average fell 0.14%.

MarketWatch Automated

Dow Jones Industrial Average

Abbott Laboratories

Becton Dickinson and

Baxter

Factset Research

West Pharmaceutical Services Inc. Stock Underperforms Wednesday When Compared To Competitors

West Pharmaceutical Services Inc. (WST) shares fell 3.17% to $312.07 on Tuesday, marking the second consecutive day of losses. The stock underperformed compared to competitors like Abbott Laboratories, Becton Dickinson, and Baxter International, which saw gains. WST is currently 5.68% below its 52-week high of $330.88 reached on May 11. The trading volume was 1.1 million, surpassing its 50-day average of 928,474.

West Pharmaceutical Services Inc. Stock Underperforms Tuesday When Compared To Competitors

ALKS

Healthcare stocks saw gains late Tuesday, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF rising about 2%. Notable movements included a 3% drop in West Pharmaceutical Services due to a cyberattack, and a 7% increase in Alkermes after positive trial results for Lumryz. Sonida Senior Living's stock decline was deemed unwarranted by RBC, which raised its price target. Dr. Reddy's Laboratories plans to launch a generic Ozempic in Canada, with its shares falling 5.3%.

Fidelity

Alkermes

Dr Reddys Laboratories

SPDR S&P Health

iShares Global Healthcare

Ark Genomic Revolution ETF

Sonida Senior Living

ROYAL BANK OF CANADA

Novo Nordisk AS

Sector Update: Healthcare Stocks Advance Late Afternoon

West Pharmaceutical Services Inc. reported a cyberattack on May 7 that disrupted operations, with data exfiltrated and systems encrypted. The company activated incident response protocols and is investigating the attack's scope. While core systems have been restored, full recovery timelines are unclear. Analysts express near-term uncertainty regarding financial impacts but commend the company's swift response. West Pharmaceutical shares fell 2.02% to $315.77, though the stock has gained 25.2% over the past month, outperforming the S&P 500.

Meta Platforms

Investors Await Damage Assessment After West Pharmaceutical Cyberattack

West Pharmaceutical(WST.US)